Lantern Pharma Receives FDA Clearance for Pediatric CNS Cancer Trial of STAR-001

Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for STAR-001, enabling a planned Phase 1 pediatric clinical trial targeting relapsed or refractory central nervous system malignancies. The study, to be conducted with the POETIC consortium across leading pediatric cancer centers, will evaluate STAR-001 alone and in combination with spironolactone, leveraging the company's RADR(R) AI platform to target DNA repair mechanisms such as ERCC3, with preclinical data showing significant survival improvements and potential to address critical unmet needs in aggressive pediatric brain cancers.

The FDA clearance represents a significant milestone for Lantern Pharma's oncology pipeline and demonstrates regulatory validation of the company's AI-driven approach to drug development. Pediatric central nervous system malignancies represent one of the most challenging areas in oncology, with limited treatment options and poor outcomes for patients with relapsed or refractory disease. The planned Phase 1 trial will investigate STAR-001's safety, tolerability, and preliminary efficacy in this vulnerable patient population, with the combination approach with spironolactone representing a novel therapeutic strategy based on the company's computational insights.

Lantern Pharma's proprietary RADR platform, which stands for Response Algorithm for Drug Positioning and Rescue, utilizes artificial intelligence and machine learning to analyze vast datasets and identify promising drug candidates and combinations. This technology has enabled the company to accelerate the development timeline for STAR-001 and optimize its therapeutic approach. The platform's ability to uncover novel therapeutic opportunities and predict patient responses represents a paradigm shift in oncology drug development, potentially reducing the time and cost associated with bringing new treatments to market.

The collaboration with the POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium) network ensures that the trial will be conducted at leading pediatric cancer centers with expertise in treating these complex malignancies. This partnership enhances the trial's scientific rigor and increases the likelihood of meaningful clinical insights. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN, providing investors and stakeholders with ongoing information about the company's progress.

This development matters because pediatric brain cancers remain among the most difficult-to-treat malignancies, with limited therapeutic options and devastating outcomes for patients and families. The application of artificial intelligence to identify and develop targeted therapies represents an innovative approach that could transform cancer treatment. By focusing on DNA repair mechanisms, STAR-001 targets a fundamental vulnerability in cancer cells while potentially sparing healthy tissue, which is particularly important in pediatric patients who are more vulnerable to treatment-related toxicities. The FDA clearance validates both the scientific rationale and the safety profile of this investigational approach, paving the way for clinical evaluation in a patient population with urgent unmet medical needs.